pembrolizumab
Agendia Building Validation Data on ImPrint for Guiding Neoadjuvant Immunotherapy in Breast Cancer
Premium
The firm envisions marketing the 53-gene signature with its existing MammaPrint and BluePrint tests as a comprehensive platform for breast cancer treatment selection.
Oncotelic Gets FDA Permission to Start Phase II Trial of TGF-B Inhibitor, Keytruda in Mesothelioma
Researchers will evaluate the combination in patients with metastatic plural mesothelioma and will explore biomarkers predictive of response.
NICE Recommends Keytruda, Chemo Combo for Advanced TNBC, Narrows PD-L1 Expression Threshold
By using a different biomarker criteria, NICE bypassed the need to compare the regimen to Tecentriq-chemo and reversed its preliminary negative recommendation from March.Â
City of Hope, Imugene Begin Trial of Oncolytic Virus in Advanced Solid Cancers
The partners will see if the oncolytic virus CF33-hNIS, dubbed Vaxinia, can increase PD-L1 tumor expression and make patients responsive to Merck's Keytruda.
Merck Nabs European Approvals for Keytruda in Cervical Cancer, Biomarker-Defined Solid Tumors
European regulators approved the agent for PD-L1-positive cervical cancer and for five tumor types defined by high microsatellite instability or DNA mismatch repair deficiency.